Empowering Health, Transforming Lives
We are focused on advancing cardiorenal innovation through integrated treatments that address unmet patient needs
Empowering Health, Transforming Lives
We are focused on advancing cardiorenal innovation through integrated treatments that address unmet patient needs
Patient-Driven
Cardiorenal Care
The scPharma Difference
Pioneering Care for the Heart and Kidney Connection
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
Patient-Driven
Cardiorenal Care
The scPharma Difference
Pioneering Care for the Heart and Kidney Connection
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
Pharmaceutical Development, Drug-Device Combinations,
and Product Commercialization Expertise
Integrated Expertise
Leading the Way in Value-Based Treatments for Heart Failure and Chronic Kidney Disease
Our focus on integrated, value-driven care positions us as a trusted leader in the industry, committed to improving patient lives and redefining healthcare standards.
Pharmaceutical Development, Drug-Device Combinations,
and Product Commercialization Expertise
Integrated Expertise
Leading the Way in Value-Based Treatments for Heart Failure and Chronic Kidney Disease
Our focus on integrated, value-driven care positions us as a trusted leader in the industry, committed to improving patient lives and redefining healthcare standards.
scPharmaceuticals
Cardiorenal Journey
-
2020
FUROSCIX Resubmission
- FUROSCIX NDA Resubmission
- Receives Complete Response Letter from FDA for FUROSCIX®
Investing in Our
Shared Future
Discover the latest insights into our company’s growth and future vision. Stay informed about the strategic decisions shaping our path forward.
Quick IR Links
Quick IR Links
Newsroom
May 14, 2025
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten...
May 07, 2025
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass. , May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations,...
May 01, 2025
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
BURLINGTON, Mass. , May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker , President and Chief Executive Officer,...
March 19, 2025
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million , and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include...
Empowering Heros on
Career Journeys
scPharmaceuticals is committed to revolutionizing cardiovascular and renal care through patient-centric approaches tailored to enhance outcomes, reduce burden, and increase quality of life.
